Occlutech was founded in Germany in 2003 and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for congenital defects, stroke prevention and heart failure.
The company´s products are sold in over 80 countries globally and the total number of implantations is exceeding 100,000, setting the highest standards for quality, outcomes and patient safety.
Occlutech maintains direct sales and clinical support operations to hospitals and physicians in Canada and Europe. Throughout the rest of the world the company works through qualified distribution partners, many of them shareholders and long-term partners.
Occlutech operates R&D and manufacturing facilities at its original site in Jena, Germany and at an additional site in Istanbul, Turkey. From Helsingborg, Sweden the company runs its global marketing support, customer service and manages global sales.
Occlutech combines several base technologies and expertise to create state-of-the-art cardiac and vascular implants. Technologies have been developed and patented by Occlutech to make a difference and allow better treatment of patients around the world. Occlutech wants to be at the forefront of new technologies and our R&D teams spend a lot of time discussing new treatment options for current and new therapeutic areas in the rapidly developing structural heart disease area.